Comparative Pharmacology
Head-to-head clinical analysis: PROMETHAZINE WITH CODEINE versus TORECAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROMETHAZINE WITH CODEINE versus TORECAN.
PROMETHAZINE WITH CODEINE vs TORECAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Promethazine is a phenothiazine derivative that antagonizes histamine at H1 receptors, acting as a sedative and antiemetic. Codeine is an opioid agonist at mu-opioid receptors, producing analgesia and antitussive effects via central nervous system depression.
TORECAN (thiethylperazine) is a phenothiazine derivative that acts primarily as a dopamine D2 receptor antagonist in the chemoreceptor trigger zone (CTZ) to exert antiemetic effects. It also possesses anticholinergic and antihistaminergic properties.
10-20 mg promethazine and 10-20 mg codeine (based on phosphate) orally every 4-6 hours as needed for cough; maximum daily codeine dose 120 mg.
10 mg orally or intramuscularly every 6 to 8 hours as needed for nausea and vomiting.
None Documented
None Documented
Promethazine: 9-16 hours (mean 12 hours), clinically significant for sedation duration. Codeine: 2.5-4 hours (mean 3 hours), with active metabolite morphine 2-3 hours.
Terminal elimination half-life: 6-8 hours. Clinical context: Allows twice-daily dosing; prolonged in renal impairment.
Promethazine: renal 70% as metabolites and unchanged drug, biliary/fecal 20-30%. Codeine: renal 90% (5-15% unchanged, rest as morphine and conjugates), fecal <10%.
Primarily renal (60-70% as unchanged drug and metabolites); biliary/fecal (20-30%).
Category A/B
Category C
Antihistamine / Antiemetic
Antiemetic